Prucalopride
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Prucalopride: Hypoalphalipoproteinemia
One-Sentence Summary
Prucalopride is a selective 5-HT4 receptor agonist (prokinetic) originally used to treat chronic constipation. The TxGNN model predicts it may be effective for hypoalphalipoproteinemia (low HDL cholesterol), but this is a computational prediction only, with 0 clinical trials and 0 publications currently supporting it.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Hypoalphalipoproteinemia |
| TxGNN Prediction Score | 0.9982 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 10 of 10) |
| Number of DINs | 10 (marketed: 10) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on known information, prucalopride is a selective 5-HT4 receptor agonist that stimulates gastrointestinal motility, and its efficacy in constipation is established.
Mechanistically, there is no known pathway connecting 5-HT4 agonism to HDL metabolism, so the prediction does not have a plausible biological explanation at present. The high score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence or pharmacological reasoning, and no trials or publications support it.
Other top-ranked predictions show the same pattern. Most are also unsupported (homozygous familial hypercholesterolemia, oral candidiasis, strongyloidiasis, HIV infection). The only partly plausible group is amyloidosis (including primary amyloidosis and amyloid neuropathy). In these, gut involvement can cause dysmotility or chronic intestinal pseudo-obstruction, where a prokinetic might relieve symptoms. This would treat GI symptoms rather than the underlying disease, and no efficacy data exist. These are better framed as research questions than as repurposing candidates for the top-ranked indication.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for hypoalphalipoproteinemia.
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02491591 | APO-PRUCALOPRIDE | Not specified | Not specified |
| 02493497 | JAMP PRUCALOPRIDE | Not specified | Not specified |
| 02550377 | NRA-PRUCALOPRIDE | Not specified | Not specified |
| 02377012 | RESOTRAN | Not specified | Not specified |
| 02377020 | RESOTRAN | Not specified | Not specified |
Five of the 10 valid single-ingredient licences are shown. All 10 are valid, and none are cancelled.
Safety Considerations
- Contraindications (knowledge graph, not label text): ulcerative colitis, inflammatory bowel disease, intestinal perforation.
- Drug Interactions: 98 interactions were found. Examples of moderate-level interactions include:
- anticholinergics (aclidinium, atropine, hyoscyamine, glycopyrronium, clidinium, benzatropine, biperiden)
- hormonal contraceptives (levonorgestrel, norethisterone, ethinylestradiol)
Minor-level examples include nifedipine, afatinib, alpelisib, amiodarone, cobicistat, captopril, diltiazem, spironolactone, carvedilol and conivaptan.
Package insert warnings and contraindications were not available, so please refer to the Health Canada package insert for full safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on a model score alone (L5). There is no mechanistic link, trial or publication for hypoalphalipoproteinemia, and the safety review cannot proceed without label data.
To proceed, the following is needed:
- Package insert warnings and contraindications from Health Canada
- Mechanism of action data (for example from DrugBank)
- A credible biological hypothesis linking 5-HT4 agonism to HDL metabolism, with preclinical or observational support
- Approved indication text and dosage forms for the Canadian licences
- Optionally, evaluation of the amyloidosis-related GI dysmotility indications as a separate research question, since they have the most plausible (though indirect) rationale
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.